ArticleFrontiers in surgery2026
Case Report: Single-incision laparoscopic sleeve gastrectomy plus jejunojejunal bypass for the treatment of type 2 diabetes in patients with obesity: a case series and review.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Single-incision laparoscopic sleeve gastrectomy plus jejunojejunal bypass (SILSG-JJB) is a novel modification of metabolic bariatric surgery. Clinical experience with this approach remains limited, particularly in patients with severe obesity and type 2 diabetes mellitus (T2DM). Case presentation: We present a case series of three female patients aged 23-30 years with severe obesity complicated by metabolic syndrome and T2DM who underwent SILSG-JJB. Perioperative course and short-term metabolic outcomes were recorded. All procedures were successfully completed through a single incision without additional port placement or conversion to open surgery. No major intraoperative or perioperative complications occurred. Postoperative recovery was uneventful, and all patients were discharged on postoperative day 3. During the short-term follow-up period, satisfactory weight loss and improvement in fasting blood glucose levels were observed, with no procedure-related adverse events or postoperative malnutrition. Conclusions: This case series demonstrates the technical feasibility and short-term safety of SILSG-JJB in selected patients with severe obesity and T2DM. Short-term follow-up indicated that SILSG-JJB could achieve significant weight reduction and improve metabolic comorbidity-related parameters, including those associated with T2DM. However, its long-term efficacy and safety in obese patients with T2DM and other metabolic complications remain to be further investigated. Further multicenter studies with larger cohorts and longer follow-up durations are required to determine its long-term efficacy, safety, and generalizability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.